When Belén Garijo, M.D., Ph.D., left the top job at Germany’s Merck KGaA to head over to Sanofi, she was inheriting a company ...

A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify t ...

Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it ...

Following a pair of FDA rejections of its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted ...

Whether it's looming tariff threats or the rise of China as a innovation powerhouse, you need a truly global view to navigate today's biopharma industry. | Whether it's looming tariff threats or the ...

Braveheart Bio, Attovia Therapeutics and Vogenx have set target ranges for their IPOs, positioning the trio to collectively ...

A panel of experts today voted against Capricor’s cell therapy for Duchenne muscular dystrophy (DMD), capping off an advisory ...

Labcorp continues to power along as it posts strong quarterly earnings led by growth in its diagnostics and lab services and ...

In potential combinations of PD-1xVEGF and TROP2 ADC, specifically, Merck also appears to be behind. China’s Minghui ...

GSK is boosting its AI chops with a new deal worth up to $110 million with Relation. | GSK is boosting its AI chops with a ...

Bristol Myers Squibb may have been noticeable by its absence from the biotech buying spree of some of its U.S. Big Pharma ...

Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill. | Apnimed has raised $192 million for its upsized IPO, with the proceeds ...